| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/19/2013 | CN101906144B Conjugate formed by conjugating one Arg-Gly-Asp-Val chain and two fatty alcohol chains by Asp, synthesis thereof and medical application thereof |
| 06/19/2013 | CN101896179B Tape preparation comprising etodolac in ionic liquid form |
| 06/19/2013 | CN101878042B Oligomer-tricyclic conjugates |
| 06/19/2013 | CN101773468B Zanamivir nasal nanometer suspension and preparation method thereof |
| 06/19/2013 | CN101744909B Walnut clove lipstick Chinese medicinal composition preparation for preventing and/or curing cheilitis |
| 06/19/2013 | CN101711753B Preparation method of lansoprazole solid preparation |
| 06/19/2013 | CN101686931B Pharmaceutical formulation for the production of chewable tablets and lozenges |
| 06/19/2013 | CN101538368B Copolymer with temperature/pH dual-sensibility and preparation and application thereof |
| 06/19/2013 | CN101522146B Transdermal therapeutic system with high rate of utilization of active substance and dosing accuracy |
| 06/19/2013 | CN101514232B RANKL-Fc fusion protein, preparation method and application thereof |
| 06/19/2013 | CN101513531B Soft capsule matrix and preparation method thereof |
| 06/19/2013 | CN101511343B Use of polyols to obtain stable polymorphous forms of rifaximin |
| 06/19/2013 | CN101249284B Biological medical nano hollow ellipsoid and preparation method and application thereof |
| 06/19/2013 | CN101224228B Panax notoginseng saponins freeze-dried powder injection and preparing method thereof |
| 06/19/2013 | CN101214227B Ambroxol hydrochloride dry powder inhalant and preparation thereof |
| 06/18/2013 | US8466277 Coupling low-molecular substances to a modified polysaccharide |
| 06/18/2013 | US8466261 Therapeutic using a bispecific antibody |
| 06/18/2013 | US8466232 Biodegradable grafted copolymers |
| 06/18/2013 | US8466139 Formulation |
| 06/18/2013 | US8466128 sodium hyaluronate mixture for topical administration to a mammalian for treating skin disorders; fungicides, corticosteroids, preservatives, antiacne agents, antibiotics |
| 06/18/2013 | US8466116 Use of CpG oligodeoxynucleotides to induce epithelial cell growth |
| 06/18/2013 | US8466102 Antimicrobial cationic peptides and formulations thereof |
| 06/18/2013 | US8465777 Diffusion-controlled dosage form and method of fabrication including three dimensional printing |
| 06/18/2013 | US8465773 Methods and compositions for treating tissue using silk proteins |
| 06/18/2013 | US8465772 Methods and compositions for treating tissue using silk proteins |
| 06/18/2013 | US8465767 Mixture with tablet distegrant; sustained release; embedding water soluble particle in plastic membrane coating ; stomach disorders |
| 06/18/2013 | US8465762 Dermal application system for aminolevulinic acid-derivatives |
| 06/18/2013 | US8465759 Process for the preparation of a hot-melt extruded laminate |
| 06/18/2013 | US8465744 Method of treating inflammation by administering human IL-1B antibodies |
| 06/18/2013 | US8465739 Stable aqueous pharmaceutical formulations of daclizumab antibodies |
| 06/18/2013 | US8465734 Methods for increasing protein polyethylene glycol (PEG) conjugation |
| 06/18/2013 | CA2705681C Corticosteroid compositions |
| 06/18/2013 | CA2699488C Conjugates of ribosome inactivating toxins with agents that bind to er+ cell receptors |
| 06/18/2013 | CA2650473C Protein crosslinkers, crosslinking methods and applications thereof |
| 06/18/2013 | CA2546637C Colonic purgative composition with soluble binding agent |
| 06/18/2013 | CA2534895C Hemostatic compositions containing sterile thrombin |
| 06/18/2013 | CA2483656C Reduced formate poly(alkylene oxide) for a controlled release dosage form of reboxetine |
| 06/18/2013 | CA2483102C Treatment and prevention of pulmonary conditions |
| 06/18/2013 | CA2481512C Peptide inhibitors of protein kinase c.gamma. for pain management |
| 06/18/2013 | CA2475923C Oral dosage form containing a pde 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient |
| 06/18/2013 | CA2446087C Recombinant tumor specific antibody and use thereof |
| 06/13/2013 | WO2013086526A1 Liposomal drug encapsulation |
| 06/13/2013 | WO2013086523A2 Injectable hydrogels |
| 06/13/2013 | WO2013086457A1 Caged compound delivery and related compositions, methods and systems |
| 06/13/2013 | WO2013086418A1 Tumor-specifc gm-csf cytokine response as predictor of cancer vaccine effectiveness |
| 06/13/2013 | WO2013086196A1 Topical formulation for administering a compound |
| 06/13/2013 | WO2013086024A2 Dermal filler compositions |
| 06/13/2013 | WO2013086015A1 Medical organogel processes and compositions |
| 06/13/2013 | WO2013085904A1 Oral spray formulations and methods for administration of sildenafil |
| 06/13/2013 | WO2013085769A1 Cellulosic gel composition with improved viscosity stability |
| 06/13/2013 | WO2013085276A1 Film for oral administration containing mirodenafil or pharmaceutically acceptable salt thereof |
| 06/13/2013 | WO2013084995A1 Adhesive patch |
| 06/13/2013 | WO2013084922A1 Bicarbonate dialysis agent |
| 06/13/2013 | WO2013084207A1 Formulations for micelle formation comprising a protein and methods preparation thereof |
| 06/13/2013 | WO2013084198A1 Chemical modification and bioconjugation of proteins or peptides using boron compounds |
| 06/13/2013 | WO2013084194A1 Topical pharmaceutical compositions of anti-microbial agents and anti-inflammatory agents |
| 06/13/2013 | WO2013083910A2 Topical emulsions based on mixtures of local eutectic anaesthetics and fatty acids as analgesics, antalgics, or as sexual retardants |
| 06/13/2013 | WO2013083817A1 Uses of immunoconjugates targeting cd138 |
| 06/13/2013 | WO2013083776A1 Dry powder formulation of azole derivative for inhalation |
| 06/13/2013 | WO2013083574A1 Composition for treating parkinson's disease. |
| 06/13/2013 | WO2013083460A1 Robust controlled-release formulations |
| 06/13/2013 | WO2013083459A1 Robust controlled-release peptide formulations |
| 06/13/2013 | WO2013082839A1 Drug-loaded liposome for overcoming tumor drug resistance, method for preparing same, and application thereof |
| 06/13/2013 | WO2013057570A3 Acrylic polymer formulations |
| 06/13/2013 | WO2013056132A3 Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof |
| 06/13/2013 | WO2013055058A9 Antibody-binding peptide-ferritin fusion protein and uses thereof |
| 06/13/2013 | WO2013032248A3 Composition for improving skin conditions, containing extracellular domain of human bone morphogenetic protein receptor 1a as active ingredient |
| 06/13/2013 | WO2013016544A4 Templated islet cells and small islet cell clusters for diabetes treatment |
| 06/13/2013 | US20130150461 Process for producing protein microparticles |
| 06/13/2013 | US20130150445 Pharmaceutical Formulations Containing Lipoic Acid Derivatives |
| 06/13/2013 | US20130150444 Modified release compositions of magnesium valproate |
| 06/13/2013 | US20130150393 Statin Bioavailability Enhancement Delivery Composition |
| 06/13/2013 | US20130150370 Taste-masked pharmaceutical formulation having accelerated onset of action |
| 06/13/2013 | US20130150338 Anti-dandruff shampoo |
| 06/13/2013 | US20130150311 Mixed poloxamer excipients |
| 06/13/2013 | US20130150296 Albumin fusion proteins |
| 06/13/2013 | US20130150287 RECOMBINANT PROTEIN FOR INTRACELLULAR DELIVERY OF siRNA AND COMPOSITION COMPRISING THE SAME |
| 06/13/2013 | US20130150281 Polymeric prodrug with self-immolative linker |
| 06/13/2013 | US20130149395 Pharmaceutical Product, Method of Production and Method of Application of the Pharmaceutical Product |
| 06/13/2013 | US20130149394 Aqueous ophthalmic composition |
| 06/13/2013 | US20130149391 Fluoride varnish compositions including an organo phosphoric acid adhesion promoting agent |
| 06/13/2013 | US20130149390 Method for Bowel Preparation |
| 06/13/2013 | US20130149380 Use of diatomaceous earth in the pharmaceutical industry |
| 06/13/2013 | US20130149379 Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract |
| 06/13/2013 | US20130149357 Porous Degradable Polyelectrolyte Microspheres as Vaccine Vector |
| 06/13/2013 | US20130149355 Hydroxyapatite-targeting poly(ethylene glycol) and related polymers |
| 06/13/2013 | US20130149350 Pharmacokinetics of S-Adenosylmethionine Formulations |
| 06/13/2013 | US20130149335 Protein formulations |
| 06/13/2013 | US20130149331 Rhamnose and forssman conjugated immunogenic agents |
| 06/13/2013 | US20130149318 Painting the pia, arachnoid, and spinal cord parenchyma |
| 06/13/2013 | US20130149298 Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| 06/13/2013 | US20130149238 Anti-VEGF Antibody Compositions and Methods |
| 06/13/2013 | US20130149237 Delivery system for diagnostic and therapeutic agents |
| 06/13/2013 | CA2858741A1 Liposomes and corresponding production method |
| 06/13/2013 | CA2858576A1 Non-ionic, low osmolar contrast agents for delivery of antisense oligonucleotides and treatment of disease |
| 06/13/2013 | CA2858366A1 Dermal filler compositions |
| 06/13/2013 | CA2858364A1 Oral spray formulations and methods for administration of sildenafil |
| 06/13/2013 | CA2858312A1 Topical emulsions based on mixtures of local eutectic anaesthetics and fatty acids as analgesics, antalgics, or as sexual retardants |
| 06/13/2013 | CA2858227A1 Robust controlled-release formulations |
| 06/13/2013 | CA2858161A1 Medical organogel processes and compositions |